Document Detail


Use of lipid-modulating drugs in complicated course of coronary heart disease.
MedLine Citation:
PMID:  18457052     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We present the results of the study of lipid-modulating drugs (pravastatin, atorvastatin, simvastatin, and fibrate gemfibrozil) in complicated coronary heart disease (acute coronary syndrome without ST elevation, chronic heart failure. In acute coronary syndrome statins produced a positive effect on some studied parameters, while in heart failure only the safety of short-term therapy with statins was demonstrated.
Authors:
N A Gratsianskii; N A Vaulin
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Bulletin of experimental biology and medicine     Volume:  144     ISSN:  0007-4888     ISO Abbreviation:  Bull. Exp. Biol. Med.     Publication Date:  2007 Sep 
Date Detail:
Created Date:  2008-05-06     Completed Date:  2008-06-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372557     Medline TA:  Bull Exp Biol Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  438-46     Citation Subset:  IM    
Affiliation:
Laboratory of Clinical Cardiology, Institute of Physicochemical Medicine, Federal Agency on Health Care and Social Development, Moscow.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antilipemic Agents / therapeutic use*
Antithrombin III / metabolism
Cholesterol, LDL / metabolism
Coronary Disease / drug therapy*
Echocardiography
Female
Gemfibrozil / therapeutic use
Heptanoic Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Male
Peptide Hydrolases / metabolism
Pravastatin / therapeutic use
Prothrombin / metabolism
Pyrroles / therapeutic use
Simvastatin / therapeutic use
von Willebrand Factor / metabolism
Chemical
Reg. No./Substance:
0/Antilipemic Agents; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/antithrombin III-protease complex; 0/von Willebrand Factor; 110862-48-1/atorvastatin; 25812-30-0/Gemfibrozil; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; 9000-94-6/Antithrombin III; 9001-26-7/Prothrombin; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Analysis of the contribution of molecular mechanisms into formation of gonoccocal resistance to tetr...
Next Document:  Pathogenetic aspects of severe course of herpetic infection.